Phase 4
Completed N=57
Liposomal Bupivacaine in Total Shoulder Arthroplasty
Source: ClinicalTrials.gov NCT02570022 ↗Enrolled (actual)
57
Serious AEs
1.8%
Results posted
Oct 2016
Primary outcomePrimary: Pain Levels — 4.8; 4.0; 4.7; 4.0 units on a scale — p=<0.05
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This is a randomized, single blinded, standard of care controlled clinical trial. All adult patients over eighteen desiring shoulder arthroplasty will be eligible. The study compares pain control and opioid consumption in patients undergoing shoulder arthroplasty between patients receiving liposomal bupivacaine and those who underwent a preoperative inter-scalene nerve block.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Levels |
4.8; 4.0; 4.7; 4.0; 4.3; 3.6 | <0.05 sig |
| SECONDARY Morphine Equivalents |
14.8; 21.4; 8.9; 9.1; 12.3; 5.2 | — |
Eligibility Criteria
Inclusion Criteria
- Patients over the age of 18 scheduled for primary shoulder arthroplasty by three fellowship trained surgeons will be eligible for inclusion
Exclusion Criteria
- Patients will be excluded if their medical history presents known allergies or intolerance to dexamethasone, opioid or bupivacaine, substantial alcohol or drug abuse, and pregnancy.
Data sourced from ClinicalTrials.gov (NCT02570022). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.